A Study of Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab Vedotin (EV) With and Without Pembrolizumab in Advanced Urothelial Carcinoma (MK-3475-04C/KEYMAKER-U04)
A phase 1/2 trial of Sacituzumab tirumotecan, Enfortumab vedotin and Pembrolizumab in bladder & urothelial cancer, run by Merck Sharp & Dohme LLC, active and no longer recruiting.
Overview
A Study of Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab Vedotin (EV) With and Without Pembrolizumab in Advanced Urothelial Carcinoma (MK-3475-04C/KEYMAKER-U04) is a phase 1/2 interventional study registered as NCT06483334 by Merck Sharp & Dohme LLC, with 38 participants enrolled, started 2024-07-17 and due to reach its primary completion in 2028-03-31. Interventions recorded: Sacituzumab tirumotecan, Enfortumab Vedotin, Pembrolizumab and Supportive care measures.
Similar pages
not linked directly; found by shared links- TrialA Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005)
Shares Enfortumab vedotin, Merck & Co. (MSD), Bladder & urothelial cancer, Pembrolizumab and the tag pipeline.
- TrialA Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027)
Shares Sacituzumab tirumotecan, Merck & Co. (MSD), Bladder & urothelial cancer and the tag pipeline.
- TrialEfficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)
Shares Merck & Co. (MSD), Bladder & urothelial cancer, Pembrolizumab and the tag pipeline.
- TrialKEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-U04)
Shares Merck & Co. (MSD), Bladder & urothelial cancer, Pembrolizumab and the tag pipeline.
- TrialSacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
Shares Sacituzumab tirumotecan, Merck & Co. (MSD), Pembrolizumab and the tag pipeline.
- TrialA Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their Bladder
Shares Enfortumab vedotin, Bladder & urothelial cancer, Pembrolizumab and the tag pipeline.
- TrialA Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
Shares Merck & Co. (MSD), Bladder & urothelial cancer, Pembrolizumab and the tag pipeline.
- TrialA Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
Shares Sacituzumab tirumotecan, Merck & Co. (MSD), Pembrolizumab and the tag pipeline.